• CDC
  • Heart Failure
  • Cardiovascular Clinical Consult
  • Adult Immunization
  • Hepatic Disease
  • Rare Disorders
  • Pediatric Immunization
  • Implementing The Topcon Ocular Telehealth Platform
  • Weight Management
  • Monkeypox
  • Guidelines
  • Men's Health
  • Psychiatry
  • Allergy
  • Nutrition
  • Women's Health
  • Cardiology
  • Substance Use
  • Pediatrics
  • Kidney Disease
  • Genetics
  • Complimentary & Alternative Medicine
  • Dermatology
  • Endocrinology
  • Oral Medicine
  • Otorhinolaryngologic Diseases
  • Pain
  • Gastrointestinal Disorders
  • Geriatrics
  • Infection
  • Musculoskeletal Disorders
  • Obesity
  • Rheumatology
  • Technology
  • Cancer
  • Nephrology
  • Anemia
  • Neurology
  • Pulmonology

Subclinical Hypothyroidism Q&A

Article

I very much appreciated Dr Douglas Ross's article, Subclinical Hypothyroidism: When to Treat, When to Watch (CONSULTANT, September 1, 2006, page 1121), and I have several questions for him.

I very much appreciated Dr Douglas Ross's article, "Subclinical Hypothyroidism: When to Treat, When to Watch" (CONSULTANT, September 1, 2006, page 1121), and I have several questions for him:

  • Are menstrual irregularities associated with subclinical hypothyroidism?
  • When you treat subclinical hypothyroidism, what should be the starting dosage of levothyroxine?
  • Once treatment has been initiated, how do you determine whether the dosage needs to be reduced or increased? Do you rely solely on the thyroid-stimulating hormone (TSH) level, or do you also take the patient's symptoms into account?

- Suzanne Barron, MS, RN, CS
  Rocky Mount, Va

Thank you for your interest in my article. Here are my responses to your questions:

  • Subclinical hypothyroidism is unlikely to cause menstrual irregularities.

  • Initial treatment of hypothyroidism, either subclinical or overt, depends on the patient. For a healthy patient, I prescribe a little less than the expected full replacement dosage, eg, 100 µg/d for a typical middle-aged woman. For elderly patients or those with underlying heart disease, a lower initial dosage followed by gradual increases is advisable. Note that because of negative feedback to pituitary production of TSH, a dose that is less than a person's normal hormone production rate will not make him or her hyperthyroid, even if he is only slightly hypothyroid before treatment.
  • With regard to monitoring therapy, I rely on TSH levels. Hypothyroid symptoms are notoriously unreliable indicators.

- Douglas S. Ross, MD
 Associate Professor of Medicine
 Harvard Medical School
 Boston

Related Videos
Donna H Ryan, MD Obesity Expert Highlights 2021 Research Success and Looks to 2022 and Beyond
Dapagliflozin slows decline of chronic kidney disease
Primary care physicians should prescribe SGLT2 inhibitors
Related Content
© 2024 MJH Life Sciences

All rights reserved.